藥明生物(02269.HK)與BioVaxys簽署生物生產協議
藥明生物(02269.HK)與加拿大生物技術公司BioVaxys Technology簽署生物生產協議,雙方將生產BioVaxys的新冠肺炎候選疫苗BVX-0320及Covid-T免疫診斷項目所需的SARS-CoV-2病毒S蛋白。
藥明生物將合成高產量的完全表徵GLP級SARS-CoV-2病毒S蛋白,用於BioVaxys的COVID-T診斷方法臨床前安全性研究。重組S蛋白將利用藥明生物的專有技術載體構建和表達,並在中試裝置反應器中進行高產蛋白生產。
BioVaxys表示,通過建立自家S蛋白來源,將能夠確保美國食品和藥物管理局(FDA)要求的純度、一致性和蛋白質表征,以及自行提供蛋白的經濟性,促進用於人體試驗的GMP級S蛋白未來生產和未來商業規模生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.